TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) Shares Purchased by Westside Investment Management Inc.

Westside Investment Management Inc. lifted its stake in TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) by 382.1% in the 1st quarter, Holdings Channel reports. The firm owned 39,225 shares of the company’s stock after purchasing an additional 31,089 shares during the quarter. Westside Investment Management Inc.’s holdings in TFF Pharmaceuticals were worth $237,000 at the end of the most recent reporting period.

Separately, Worth Venture Partners LLC raised its position in TFF Pharmaceuticals by 66.2% during the third quarter. Worth Venture Partners LLC now owns 646,832 shares of the company’s stock worth $226,000 after acquiring an additional 257,722 shares during the last quarter. 15.25% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Roth Mkm cut their target price on shares of TFF Pharmaceuticals from $56.00 to $44.00 and set a “buy” rating for the company in a research report on Thursday, March 28th.

TFF Pharmaceuticals Stock Performance

Shares of TFFP opened at $1.81 on Thursday. The company has a 50-day moving average of $2.07 and a two-hundred day moving average of $4.71. TFF Pharmaceuticals, Inc. has a 12-month low of $1.54 and a 12-month high of $13.50.

TFF Pharmaceuticals (NASDAQ:TFFP) last announced its earnings results on Tuesday, May 14th. The company reported ($2.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.20) by ($0.20). The business had revenue of $0.20 million for the quarter, compared to analyst estimates of $0.15 million. TFF Pharmaceuticals had a negative return on equity of 195.14% and a negative net margin of 2,251.52%. On average, equities research analysts expect that TFF Pharmaceuticals, Inc. will post -6.51 earnings per share for the current year.

TFF Pharmaceuticals Company Profile

TFF Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions.